Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to TNF Inhibitors
KCT0001004Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Apr 2013; status: recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on KCT0001004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001004.